Feed Insights Top Reports Pricing

⌘K

17:17:56·796d

SECFilingvia Quantisnow

SEC Form 10-Q filed by Vaccinex Inc.

ByQuantisnow·Wall Street's wire, on your screen.

VCNX· Vaccinex Inc.

Health Care

#watchlistBeagle is online

BeagleApp5:17 PM

Heads up - $VCNX just posted a new SEC filing. Here is the headline that moved it:

SEC Form 10-Q filed by Vaccinex Inc.

Sourced from the filing - want the 30-second brief? Never financial advice.

Hire Beagle to watch $VCNX

👀7🚀4🐶3

Plus alert sent

Quantisnow Plus members were alerted at 17:17:58 ET - 2.2s after publication.

Sign up for Plus

beagle.

by Alamere Labs

Now hiring

Your first full-time market-watch teammate

Market research that briefs you, before the bell.

Beagle watches $VCNX across price, news, SEC filings and the macro calendar, drafts the morning brief, and pings you the moment a name moves - sourced every time, and never financial advice.

Price levelsSEC filingsBreaking newsMacro calendar

Hire Beagle See an alertLives in Slack & Teams

Free Quantisnow account

Get notified the moment VCNX files

Real-time alerts on SEC filings, FDA approvals, analyst ratings, insider trades, and press releases. Follow any ticker. No credit card.

Sign up free Log in

Original source

This insight was delivered by Quantisnow - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VCNX (Vaccinex Inc.) and more on Quantisnow.

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
Vaccinex Reports 2025 Annual Financial Results
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds Follow on Google News

Top lists

Trending By market cap Active companies Insider purchases FDA approvals Short volume screener Sectors Market reports

Browse

By event category By exchange Earnings calendar Dividend tracker Insider tracker IPO calendar Compare stocks

Publish

Publish an article Amend a newsitem Pricing Guidelines Terms

Company

About Pricing Refer a trader25%Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022